SOPH News & Events

"2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth," said Jurgi Camblong, CEO. "Our strong performance in 2025 positions us well for continued growth in 2026 and beyond. Growth catalysts for the year ahead include our best-in-class Liquid Biopsy application MSK-ACCESS(R) powered with SOPHiA DDM(TM), valuable opportunities in the U.S. market, and a reinvigorated BioPharma business. We look forward to continuing to demonstrate operating leverage in 2026 and have high confidence in a material improvement in our financial position."

The company "performed over 105,000 analyses on SOPHiA DDM(TM) in the fourth quarter, representing 16% year-over-year growth." In FY25, performed over 391,000 analyses on SOPHiA DDM(TM) in 2025, a new company record.

The company guides FY26 revenue between $92 million and $94 million, representing approximately 20% to 22% year-over-year growth. Adjusted EBITDA loss between $29 million and $32 million."